We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries Ltd. is a member of our Medical group, which includes 1025 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Teva Pharmaceutical Industries Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 0.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, TEVA has gained about 67.5% so far this year. Meanwhile, stocks in the Medical group have gained about 7.5% on average. This means that Teva Pharmaceutical Industries Ltd. is outperforming the sector as a whole this year.
Adaptive Biotechnologies (ADPT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 12.7%.
The consensus estimate for Adaptive Biotechnologies' current year EPS has increased 7.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Teva Pharmaceutical Industries Ltd. belongs to the Medical - Generic Drugs industry, which includes 11 individual stocks and currently sits at #27 in the Zacks Industry Rank. On average, this group has gained an average of 16.7% so far this year, meaning that TEVA is performing better in terms of year-to-date returns.
On the other hand, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry. This 504-stock industry is currently ranked #83. The industry has moved -0.3% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Teva Pharmaceutical Industries Ltd. and Adaptive Biotechnologies as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries Ltd. is a member of our Medical group, which includes 1025 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Teva Pharmaceutical Industries Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 0.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, TEVA has gained about 67.5% so far this year. Meanwhile, stocks in the Medical group have gained about 7.5% on average. This means that Teva Pharmaceutical Industries Ltd. is outperforming the sector as a whole this year.
Adaptive Biotechnologies (ADPT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 12.7%.
The consensus estimate for Adaptive Biotechnologies' current year EPS has increased 7.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Teva Pharmaceutical Industries Ltd. belongs to the Medical - Generic Drugs industry, which includes 11 individual stocks and currently sits at #27 in the Zacks Industry Rank. On average, this group has gained an average of 16.7% so far this year, meaning that TEVA is performing better in terms of year-to-date returns.
On the other hand, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry. This 504-stock industry is currently ranked #83. The industry has moved -0.3% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Teva Pharmaceutical Industries Ltd. and Adaptive Biotechnologies as they could maintain their solid performance.